Tratamento dos distúrbios respiratórios do sono com retentor lingual: ensaio clínico randomizado cross-over

• Autor(a) principal: Jung, Aline [UNIFESP]
• Data de Publicação: 2018
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• dARK ID: ark:/48912/001300000d09n
• Texto Completo: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=6628660; https://repositorio.unifesp.br/handle/11600/52536
• topic: Obstructive sleep apnea syndrome; Tongue stabilizing device; Tongue retaining device; Oral appliance; OSAS; Síndrome da apneia obstrutiva do sono; Aparelho intraoral; Aparelho retentor lingual; Aparelho estabilizador lingual; SAOS

Objective. Check the efficiency of the dental appliance retainer lingual TSD (Tongue Stabilizing Device) in the treatment of Obstructive Sleep Apnea Syndrome (OSAS). Method. Randomized Clinical Trial Cross-over 64 patients with polysomnographic diagnosis of obstructive sleep apnea. Patients were randomized into two groups, one treated with TSD and another treated with acetate plate as control (CG) for 4 weeks. After 2 weeks of wash-out, the treatments were exchanged and the patients used the new device for 4 weeks. They were assessed with polysomnography, daily use and adverse events. Results: Patients who used the TSD device compared to control group had lower apneahypopnea index (AHI) (11.5±10.6 events/hour versus 14.8±11.7 events/hour, p <0.05), and more discontinuing use because of adverse events (18 patients, 28,1% versus 1 patient, 1.6%; p <0.05). Of the patients treated with TSD, 25 (39%) had a reduction in AHI and 14 (22%) patients reduced AHI to less than 5. TSD patients younger than 56 years compared to those older than 56 years had a lower AHI (8.1 ± 5.9 events/hour versus AHI 14.9 ± 13.4 events/hour, p <0.05), higher TTS (357.4 ± 64.8min versus 323.1 ± 48.8min; p <0.05) and better sleep efficiency (84.2 ± 9.7% versus 77.3 ± 7.4%, p <0.05). Conclusion: The treatment of mild and moderated OSA with TSD is an option that can benefits only a few number of patients. The reduction of respiratory events in the treated group was small, and only a fifth of the patients normalized the number of the events. The TSD connected to side effects that motivated the suspension of a high number of the patients.